Ataxia-Telangiectasia (A-T) is an autosomal recessive human disease characterized by genetic instability, radiosensitivity, immunodeficiency and cancer predisposition, because of mutation in both alleles of the ATM (ataxiatelangiectasia mutated) gene. The role of Atm heterozygosity in cancer susceptibility is controversial, in both human and mouse. Earlier studies identified deletions near the Atm gene on mouse chromosome 9 in radiationinduced lymphomas from p53 heterozygous mice. To determine whether Atm was the target of these deletions, Atm heterozygous as well as Atm/P53 double heterozygous mice were treated with ionizing radiation. There were no significant differences in tumor latency, progression and lifespan after c-radiation in Atm heterozygous mice compared with their wild-type control counterparts. Deletions were found on chromosome 9 near the Atm locus in radiation-induced tumors, but in 50% of the cases the deletion included the knockout allele, and the expression of Atm was maintained in the tumors indicating that loss of heterozygosity on chromosome 9 is not driven by Atm, but by an alternative tumor suppressor gene located near Atm on this chromosome. We conclude that Atm heterozygosity does not confer an increase in tumor susceptibility in this context.
Mutations in the ATM gene cause the human syndrome known as Ataxia-Telangiectasia (A-T), an autosomal recessive disorder associated with increased radiation sensitivity, neuropathies and immunological disorders. A percentage of patients with A-T syndrome develop cancer, mainly T-cell leukemias and B-lymphomas (Taylor et al., 1996) . Whereas A-T is a relatively rare disease, human heterozygous carriers of ATM mutations are relatively common, being approximately 1-3% of the human population (Swift et al., 1991) . It has been suggested that these individuals with mutations in only one ATM allele have a higher risk of developing breast and other cancers including lung, gastric and lymphoid tumors (Swift et al., 1991; Athma et al., 1996; Inskip et al., 1999; Olsen et al., 2001) ; however, other studies do not support an elevated risk of cancer in ATM mutation carriers (Wooster et al., 1993; Vorechovsky et al., 1996; FitzGerald et al., 1997; Chen et al., 1998) .
Atm knockout heterozygous mice do not seem to develop spontaneous tumors (Spring et al., 2002) , but exhibit increased sensitivity to radiation with decreased survival, premature graying and cataracts (Barlow et al., 1999; Worgul et al., 2002) . The challenge to these mice with different toxic and oncogenic agents, or crossing them with different oncomice, shows controversial results (Karabinis et al., 2001; Bowen et al., 2005; Lu et al., 2006) , and the spectrum of tumor types after ionizing radiation was not different from that observed in Atm wild-type mice (Barlow et al., 1999) .
We demonstrated earlier that deletions occur in the region of mouse chromosome 9 containing the Atm gene in lymphomas induced by ionizing radiation (Cai et al., 2002; Mao et al., 2004) . In this study, to determine whether Atm may be the target for these deletions, a group of Atm heterozygous and control mice received a 4 Gy single dose of g-irradiation, and all the mice were monitored daily for tumor development. Unexpectedly, the Atm heterozygous mice did not develop significantly more tumors than their corresponding controls, and there were no differences in the lifespan (Figure 1) . Only a small number of mice developed tumors after 1 year, but there were no statistically significant differences between Atm heterozygous and wild-type mice with respect to tumor development (P-value ¼ 0.28) (Figure 1) .
Since it is well demonstrated that complete deficiency of Atm increases susceptibility to lymphoma development in mice (Barlow et al., 1996; Elson et al., 1996; Xu et al., 1996) , our results suggest that a single allele of Atm might be enough to confer protection against tumor development, even after radiation exposure. These results seem to be in contradiction with what it has been reported earlier regarding Atm haploinsufficiency in mice after sublethal doses of ionizing radiation (Barlow et al., 1999) . The disparity with our data could be explained by differences in the genetic background of the mice. Whereas Barlow et al. used F1-129/svEv:NIH black Swiss background, we utilized an intercross between 129/sv and C57Bl6/J, in which wild-type mice from the same litters were used as controls to eliminate any possible genetic background effects. Interestingly, it has been demonstrated that Atm/P53 double-heterozygous mice are more susceptible to breast cancer development in BALB/c mice (Umesako et al., 2005) , a genetic background already susceptible to breast cancer, probably because of an intrinsic DNA-dependent protein kinase catalytic subunit deficiency (Yu et al., 2001) . The putative Atm suppressor function depending on the genetic background might explain the different results in tumor susceptibility obtained from human A-T carriers (Swift et al., 1991; Wooster et al., 1993; Athma et al., 1996; Vorechovsky et al., 1996; FitzGerald et al., 1997; Chen et al., 1998; Inskip et al., 1999; Olsen et al., 2001) and Atm heterozygous mice (Bowen et al., 2005; Umesako et al., 2005; Karabinis et al., 2001; Lu et al., 2006) . In fact, it has been proposed that ATM might function as a low-penetrance susceptibility gene (Bishop and Hopper, 1997) . In this case, ATM mutations may predispose A-T carriers to tumor susceptibility only in concert with other mutations or polymorphic variants.
As our earlier studies identified chromosome 9 deletions in tumors from p53 heterozygous mice, we tested the possibility that Atm heterozygosity may contribute to tumor susceptibility only in the context of p53 deficiency. The Atm and p53 pathways interact in a number of ways, including response to DNA damageinduced cell-cycle checkpoints, cellular proliferation, apoptosis and radiation sensitivity (Nakamura, 1998) .
Furthermore, both Atm null mice (Barlow et al., 1996; Elson et al., 1996; Xu et al., 1996) , and those null for p53 (Donehower et al., 1992; Jacks et al., 1994) develop preferentially T-cell lymphomas. Moreover, it has been suggested that Atm and p53 cooperate in suppression of tumorigenesis in vivo (Westphal et al., 1997) , but to our knowledge, the interaction of these two genes at organism level in a double heterozygous genetic context to analyze lymphoma susceptibility has not been studied. Thus, to determine whether Atm deficiency collaborates with the loss of p53 in thymic lymphoma development, single p53 and double p53/Atm heterozygous mice from the same litters received a single 4 Gy dose of g irradiation, followed by daily monitoring for tumor development. Unexpectedly, there were no significant differences in tumor spectrum, histopathology and lifespan between single p53 and double p53/Atm heterozygous mice (P-value ¼ 0.85) (Figure 1 and Supplementary Figure 1) .
Since it has been shown that all tumors that develop in p53 heterozygous mice have lost the remaining wildtype p53 allele after radiation (Kemp et al., 1994) , we questioned whether there was loss of the functional Atm allele in tumors from single or double heterozygous mice. We investigated the existence of Atm deletions by microsatellite analysis in lymphomas from double p53/ Atm heterozygous mice. Whereas we confirmed the loss of the p53 wild-type allele in 100% of tumors (Figure 2a) , the wild-type Atm allele presented a more complex scenario. The gene encoding Atm is located on chromosome 9, and loss of heterozygosity in this region has been reported earlier in radiation-induced lymphomas (Cai et al., 2002; Mao et al., 2004) . In agreement with these results, the Atm locus was deleted in 2 out of 5 tumors from Atm single and 12 out of 25 tumors from double p53/Atm heterozygous mice; interestingly, the Atm locus in single p53 heterozygous mice was deleted with a similar frequency (55.6%; data not shown). However, the deletion from double p53/Atm heterozygous mice involved the knockout allele in about 50% of the tumors (Figures 2a and b) , indicating that loss of heterozygosity on chromosome 9 is not driven by Atm, but by an alternative tumor suppressor gene located near Atm in this chromosome. To determine whether the remaining wild-type Atm allele was inactivated by other mechanisms leading to loss of expression in the tumors, we carried out reverse transcription-PCR analysis to detect Atm expression. In all tumors studied from single p53 and double p53/Atm the remaining Atm allele was expressed (Figure 3) , and no mutations were found in Atm by sequence analysis of the complete coding region (data not shown) (Supplementary Table 1 ). This is surprising, considering the number of connections of Atm with other tumor suppressor pathways in vitro apart from p53 (Shiloh, 2003; Matsuoka et al., 2007) and suggests that Atm tumor suppressor function can be compensated in vivo by redundant pathways.
It has been demonstrated earlier that mice that are double null for Atm and p53 exhibit an acceleration of tumor formation relative to singly null mice (Westphal et al., 1997) , suggesting that after the loss of the second Figure 1 Radiation-induced tumorigenesis in wild-type, Atm þ /À, p53 þ /À and Atm þ /Àp53 þ /À mice. Atm þ /À and p53 þ /À mice, from 129/sv and C57BL6/J background, respectively were purchased from Jackson Laboratory (ME, USA) and intercrossed to obtain all the genotypes under study within the same litters. All mice received a single dose of 4 Gy whole body g-radiation at the age of 5 weeks, and were monitored afterwards daily until moribund, then sacrificed and autopsied. There were no statistically significant differences between wild type and Atm þ /À (P ¼ 0.28), and between p53 þ /À and Atm þ /Àp53 þ /À (P ¼ 0.85) mice by Kaplan-Meier analysis using the SPSS software.
Tumor susceptibility in Atm þ /À mice JH Mao et al allele of p53 there may be additional selection for loss of the second allele of Atm. Our data suggest that selection acts only against the second allele of p53 and not against Atm during tumor progression. As it has been shown that loss of Atm radiosensitizes p53-null tissues (Westphal et al., 1998), it might be possible that those cells Interestingly, in about half of the cases the Atm locus deleted was the knocked one from the 129/sv background origin (tumors 5, 7, 9, 10, 11 and 13), indicating that Atm is not the driving force at the chromosome 9 deletion. D9Mit97 PCR primers were purchased from Qiagen Operon (Alameda, CA, USA). PCR reactions were set up in a total volume of 20 ml of 10 Â PCR buffer (Bioline USA Inc., Reno, NV, USA), 1.6 ml of 2.5 dNTPs (Pharmacia Biosystem Ltd, Milton Keynes, UK), 1 ml (6.6 mM) or each prime, 0.6 ml of 50 mM MgCl2 (Bioline), 11.7 ml ddH2O, 0.1 ml Taq polymerase (Bioline) and 2 ml (40 ng/ml) tumor or normal tissue DNA. Amplifications were initially denatured at 94 1C for that lose the remaining Atm allele after the second allele of p53 die by apoptosis. This reinforces the necessity of a specific order of occurrence of the oncogenic events that take place in cancer progression, as has been proposed in classical models of different tumor types such as colon, skin, pancreas or radiation-induced lymphoma among others (Burns et al., 1991; Cho and Vogelstein, 1992; Hansel et al., 2003; Mao et al., 2004) .
Our results suggest that monoallelic deficiency of Atm in the context of p53 heterozygosity does not increase tumor susceptibility. Although this is in agreement with the observation that Atm haploinsufficiency did not alter the radiation mutagenic responses (Connolly et al., 2006) , our results do not exclude the possibility that Atm heterozygous deficiency might increase tumor risk in other contexts. These could be related to the type of ATM mutation (Gatti et al., 1999; Teraoka et al., 2001; Spring et al., 2002) , or to the genetic background (Umesako et al., 2005) , if ATM acts as low penetrance susceptibility gene in the context of other genetic interactions (Bishop and Hopper, 1997) . This could explain not only the controversial findings in A-T carriers, but also the absence of complete penetrance of tumor development in A-T patients, which is around 10-15% (Taylor et al., 1996) . The 100% penetrance of tumor susceptibility in Atm null mice (Barlow et al., 1996; Elson et al., 1996; Xu et al., 1996) suggests that it may be necessary to develop new in vivo strategies to study the genetic interactions of Atm as a low penetrance modifier gene of tumor susceptibility (Balmain, 2002) . These strategies might help to better dissect and understand Atm genetic interactions and ultimately permit individual genetic counseling for A-T carriers.
